Biocatalysts and methods for the synthesis of armodafinil

US9365835B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9365835-B2
Application numberUS-201614997277-A
CountryUS
Kind codeB2
Filing dateJan 15, 2016
Priority dateDec 8, 2010
Publication dateJun 14, 2016
Grant dateJun 14, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates to non-naturally occurring polypeptides useful for preparing armodafinil, polynucleotides encoding the polypeptides, and methods of using the polypeptides. The non-naturally occurring polypeptides of the present invention are effective in carrying out biocatalytic conversion of the (i) 2-(benzhydrylsulfinyl)acetamide to (−)-2-[(R)-(diphenylmethyl)sulfinyl]acetamide (armodafinil), or (ii) benzhydryl-thioacetic acid to (R)-2-(benzhydrylsulfinyl)acetic acid, which is a pivotal intermediate in the synthesis of armodafinil, in enantiomeric excess.

First claim

Opening claim text (preview).

What is claimed is: 1. A non-naturally occurring polynucleotide encoding a polypeptide having cyclohexanone monooxygenase (CHMO) activity wherein the amino acid sequence of the polypeptide has at least 95% sequence identity to SEQ ID NO: 136. 2. The polynucleotide of claim 1 , wherein said encoded polypeptide is capable of converting the acid substrate (1b) to compound (2b) (R-enantiomer) or its opposite enantiomer compound (S-enantiomer) with at least 2-fold improved activity relative to the wild-type polypeptide of SEQ ID NO: 2, 3. The polynucleotide of claim 2 , wherein said encoded polypeptide is capable of converting the acid substrate of compound (1b) to the R-enantiomer compound (2b) in at least 50% enantiomeric excess. 4. The polynucleotide of claim 1 , wherein said encoded polypeptide is capable of converting compound (1a) to compound (2a) in at least 75%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% enantiomeric excess under suitable reaction conditions. 5. The polynucleotide of claim 4 , wherein said encoded polypeptide is capable of converting compound (1a) to compound (2a) with an activity increased at least 2-fold, at least 4-fold, at least 10-fold, at least 25-fold, at least 40-fold, or at least 60-fold relative to the activity of the polypeptide of SEQ ID NO: 2 under suitable conditions. 6. The polynucleotide of claim 1 , wherein said encoded polypeptide is capable of converting compound (1b) to compound (2b) in enantiomeric excess under suitable reaction conditions. 7. The polynucleotide of claim 6 , wherein said encoded polypeptide is capable of converting compound (1b) to compound (2b) in at least 75%, at least 85%, at least 90%, at least 95%, at least 98% or at least 99% enantiomeric excess under suitable reaction conditions. 8. The polynucleotide of claim 2 , wherein said encoded polypeptide is capable of converting compound (1b) to compound (2b) with an activity increased at least 2-fold, at least 4-fold, at least 10-fold, at least 25-fold, at least 40-fold, or at least 60-fold relative to the activity of the polypeptide of SEQ ID NO: 38 under suitable reaction conditions. 9. The polynucleotide of claim 2 , wherein said encoded polypeptide is capable of at least 90% or greater conversion of compound (1b) to compound (2b) in 24 h with a substrate loading of about 50 g/L. 10. The polynucleotide of claim 1 , wherein the polynucleotide encodes a polypeptide which comprises the amino acid sequence of SEQ ID NO: 90, 96, 98, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140 or 142.

Assignees

Inventors

Classifications

  • Amides, e.g. chloramphenicol {or polyamides; Imides or polyimides; Urethanes, i.e. compounds comprising N-C=O structural element or polyurethanes (peptides C12P21/00 or C07K)} · CPC title

  • C12N9/0073Primary

    with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13 · CPC title

  • Cyclohexanone monooxygenase (1.14.13.22) · CPC title

  • Preparation of sulfur-containing organic compounds · CPC title

  • using catalysts, e.g. selective catalysts · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9365835B2 cover?
The present invention relates to non-naturally occurring polypeptides useful for preparing armodafinil, polynucleotides encoding the polypeptides, and methods of using the polypeptides. The non-naturally occurring polypeptides of the present invention are effective in carrying out biocatalytic conversion of the (i) 2-(benzhydrylsulfinyl)acetamide to (−)-2-[(R)-(diphenylmethyl)sulfinyl]acetamide…
Who is the assignee on this patent?
Codexis Inc
What technology area does this patent fall under?
Primary CPC classification C12N9/0073. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jun 14 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).